Daily Judi: Thursday, September 8, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
Avian influenza, or bird flu, has spread to the cetacean population, recently detected in a Florida dolphin, and a porpoise in Sweden. (NY Times)
Reuters reports that Dutch multinational Philips is under investigation by prosecutors in France, relating to a respiratory device recall. The medical device maker is in settlement negotiations now with the United States Department of Justice over a recall of sleep apnea machines and ventilators.
Wired looks at the effectiveness of the latest mRNA COVID-19 boosters, designed to protect against widely circulating Omicron variants.
The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!
We also hope to see you this September 13-14, in Boston, for DPHARM: Disruptive Innovations to Advance Clinical Trials, walking distance from our North End headquarters.
Attending the annual conference of the Society for Clinical Data Management in San Antonio, Texas (SCDM2022)? Join AG Mednet's Abraham Gutman in a roundtable discussion on how imaging quality control automation improve endpoint data, Monday, September 12, 2022, 1:45 to 2:45 p.m.
“We are small enough that we are nimble, so we can prioritize quickly, yet also of significant size that we allocate resources where needed. We truly do a lot. This is my dream job. Judi allows me to have a bigger impact. And we do great work.”
–Jess, Program Manager
Judi empowers and enhances the world's clinical trial ecosystems. Our cloud-based platform has 110,000 users across 140 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.